UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28.823

Sortiert nach

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

Annals of oncology, 2009-04, Vol.20 (4), p.666-673

2009

Link zum Volltext

Verfügbarkeit prüfen

Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint

Terapevtic̆eskii arhiv, 2023-12, Vol.95 (12), p.1141

2023

Link zum Volltext

Verfügbarkeit prüfen

Topical application of hypotensive drugs for the prevention of intraocular pressure elevation after intravitreal injections of anti-VEGF drugs

Vestnik oftal'mologii, 2024, Vol.140 (2. Vyp. 2), p.73

2024

Link zum Volltext

Verfügbarkeit prüfen

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Annals of oncology, 2011-01, Vol.22 (1), p.39-48

2011

Link zum Volltext

Verfügbarkeit prüfen

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

Clinical cancer research, 2013-05, Vol.19 (9), p.2541-2550

2013

Link zum Volltext

Verfügbarkeit prüfen

Block ionomer complexes of PEG-block-poly(4-vinylbenzylphosphonate) and cationic surfactants as highly stable, pH responsive drug delivery system

Journal of controlled release, 2012-06, Vol.160 (3), p.486-494

2012

Link zum Volltext

Verfügbarkeit prüfen

Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters

European journal of pharmaceutics and biopharmaceutics, 2010-02, Vol.74 (2), p.157-163

2010

Link zum Volltext

Verfügbarkeit prüfen

First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study

Annals of oncology, 2012-01, Vol.23 (1), p.111-118

2012

Link zum Volltext

Verfügbarkeit prüfen

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Blood, 2012-04, Vol.119 (15), p.3403-3412

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

Annals of oncology, 2012-07, Vol.23 (7), p.1803-1808

2012

Link zum Volltext

Verfügbarkeit prüfen

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

Annals of oncology, 2007-05, Vol.18 (5), p.859-867

2007

Link zum Volltext

Verfügbarkeit prüfen

The use of antioxidants in combination therapy of chronic prostatitis

Urologii͡a︡ (Moscow, Russia : 1999), 2024-03 (1), p.162

2024

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Clinical cancer research, 2011-11, Vol.17 (21), p.6822-6830

2011

Link zum Volltext

Verfügbarkeit prüfen

Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

BJU international, 2004-02, Vol.93 (3), p.303-310

2004

Link zum Volltext

Verfügbarkeit prüfen

Pharmacoeconomic analysis of anti-angiogenic drugs for diabetic macular edema

Vestnik oftal'mologii, 2024, Vol.140 (2), p.112

2024

Link zum Volltext

Verfügbarkeit prüfen

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

British journal of cancer, 2013-02, Vol.108 (3), p.503-511

2013

Link zum Volltext

Verfügbarkeit prüfen

Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

Annals of oncology, 2001-09, Vol.12 (9), p.1247-1254

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Blood, 2009-06, Vol.113 (25), p.6322-6329

2009

Link zum Volltext

Verfügbarkeit prüfen

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

Annals of oncology, 2011-01, Vol.22 (1), p.49-58

2011

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial

Lung cancer (Amsterdam, Netherlands), 2006-05, Vol.52 (2), p.155-163

2006

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study

Terapevtic̆eskii arhiv, 2018-08, Vol.90 (8), p.27

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection

Terapevtic̆eskii arhiv, 2018-08, Vol.90 (8), p.33

2018

Link zum Volltext

Verfügbarkeit prüfen

Systemic therapy of soft tissue sarcomas

Voprosy onkologij, 2015, Vol.61 (2), p.252

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 28.823

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

KollektionUniversal Database of Russian Military & Security Periodicals

SpracheRussisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20.395)
Mit Volltextzugriff
(614)

Publikationsform

Sprache

Englisch
(1.047)
Japanisch
(29)
Bulgarisch
(8)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(19.965)
Male
(13.093)
Female
(11.016)
Animals
(10.078)
Adult
(9.047)
Middle Aged
(8.836)
Time Factors
(5.676)
Rats
(4.609)
Aged
(4.551)
Adolescent
(4.115)
Treatment Outcome
(3.236)
Drug Therapy, Combination
(2.727)
Child
(2.462)
Mice
(2.292)
Dose-Response Relationship, Drug
(2.235)
Science & Technology
(2.040)
Life Sciences & Biomedicine
(2.036)
Rabbits
(1.523)
Child, Preschool
(1.493)
Drug Evaluation
(1.442)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Terapevtic̆eskii Arhiv
(1.680)
Žurnal Mikrobiologii, Ėpidemiologii I Immunobiologii
(1.148)
Kardiologiia
(1.111)
Anesteziologiia I Reanimatologiia
(992)
Klinicheskaia Meditsina
(951)
Voprosy Pitaniia
(937)
Biulleten' Eksperimental'noi Biologii I Meditsiny
(862)
Vestnik Hirurgii Im. I.I. Grekova
(852)
Problemy Tuberkuleza
(832)
Voprosy Onkologij
(822)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(25)
... seit 30 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint

Topical application of hypotensive drugs for the prevention of intraocular pressure elevation after intravitreal injections of anti-VEGF drugs

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

Block ionomer complexes of PEG-block-poly(4-vinylbenzylphosphonate) and cationic surfactants as highly stable, pH responsive drug delivery system

Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters

First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

The use of antioxidants in combination therapy of chronic prostatitis

Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

Pharmacoeconomic analysis of anti-angiogenic drugs for diabetic macular edema

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial

Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study

Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection

Systemic therapy of soft tissue sarcomas

Aktive Filter

Suchergebnisse filtern